VCBeat Health Contact Us
Home Bangyo Bio Announces Over RMB 200 Million Series B Financing to Accelerate Cell and Gene Therapy Drug Development

Bangyo Bio Announces Over RMB 200 Million Series B Financing to Accelerate Cell and Gene Therapy Drug Development

Nov 14, 2022 08:00 CST Updated 08:00
BRL Medicine

Cell and Gene Therapy Drug Developer

Oriental Fortune Capital

Professional Venture Capital Management Firm

BRL Medicine
Series AShanghai2013-09
Gene Editing and Cell Therapy Developer
36Kr ReportHealthcare
I Want to Contact